The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The RSV vaccination eligibility age has been lowered from 60 years to 50 years according to an update on the CDC website.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal viruses like flu and RSV. Learn about the symptoms, preventive measures, and ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

Individuals who received either the AS01 shingles or RSV vaccine had a significantly lower risk of developing dementia.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for respiratory syncytial virus.